Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ablaze Closes $75 Million Series for Targeted Radiopharmaceutical Therapies

publication date: Nov 29, 2021

Ablaze Pharmaceuticals, a Shanghai-San Diego company, closed a $75 million Series A round for China development of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets. Ablaze was founded by RayzeBio, a San Diego company that also focuses on TRT candidates. Ablaze will bring RayzeBio's products to China along with products from other companies. The A round was co-led by Vivo Capital and AdvanTech Capital with participation from RAYZ Investments and others.  More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital